SK bioscience bags fresh backing to accelerate fight against respiratory disease
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production
At the center of the collapse is opposition from the Federal Trade Commission
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
SPARK has extended its influence to an additional 9.47 million students worldwide
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Subscribe To Our Newsletter & Stay Updated